The Evolution of Immunotherapy Against Tumors
An Historical Approach
- 1st Edition - August 27, 2024
- Imprint: Academic Press
- Author: Domenico Ribatti
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 2 1 7 9 8 - 2
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 1 7 9 9 - 9
The Evolution of Immunotherapy Against Tumors: An Historical Approach summarizes the literature concerning the development of the theory of immune surveillance against tumors. I… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThe Evolution of Immunotherapy Against Tumors: An Historical Approach summarizes the literature concerning the development of the theory of immune surveillance against tumors. It discusses the evidence for and against this theory, along with the concept of immunoediting. Finally, current approaches in anti-tumor immunotherapy will be analyzed.
The immune system plays a major role in the surveillance against tumors. To avoid attack from the immune system, tumor cells develop different strategies to escape immune surveillance. Evidence of immune surveillance comes from both animal models and clinical observations. Mice with a wide variety of immunodeficiencies have a high rate of tumor incidence and are more susceptible to transplanted or chemical carcinogen-induced tumors. Immunosuppressed patients have a high incidence of tumors. However, many patients develop cancer even in the presence of an apparently normal immune system. This indicates that tumor cells can escape immune surveillance.
- Covers the experimental approaches to investigate immunotherapy against tumors
- Provides a comprehensive overview of the pharmacological tools in this field
- Serves as a reference book to researchers in the respective fields and related disciplines
Researchers, students, teachers, and industry professionals, academic institutions, senior and junior academic researchers, pharmaceutical companies, and research institutions, PhD students, undergraduate students and postdoctoral fellows
- Cover image
- Title page
- Table of Contents
- Copyright
- Preface
- 1. Historical background
- The primordia
- Jenner and the vaccinology
- Metchnikoff and the discovery of macrophages
- Ehrlich and the side-chain theory of antibody formation
- The natural selection hypothesis and the clonal selection theory
- The discovery of the structure of antibodies
- Diversity of antibody specificities
- The discovery of the primary immune organs
- Immunodeficiencies
- B cells, T cells, and other effector cells of the immune response
- The major histocompatibility complex and immunological tolerance
- Immunotherapy
- 2. First evidence
- 3. Bacillus Calmette–Guerin
- 4. Immunosurveillance against tumors
- Evidence confirming the theory of immunosurveillance
- Evidence against the theory of immunosurveillance
- 5. Immunoediting
- 6. Inflammation and tumors
- Tumor hypoxia
- Tumor vasculature
- Tumor angiogenesis
- Alternative mode of tumor vascularization
- Genomic instability of tumor endothelial cells and increase of metastatic potential
- Inhibition of angiogenesis
- Tumor-associated macrophages
- Tie-2 expressing monocytes
- B lymphocytes
- T lymphocytes
- T regulatory cells
- Natural killer cells
- Tumor associated neutrophils
- Mast cells
- Cancer associated fibroblasts
- Dendritic cells
- Myeloid-derived suppressor cells
- 7. Therapeutic implications
- 8. Cytokine therapies
- Basic immunotherapy with IL-2
- Interferons
- 9. Adoptive T cell therapy
- 10. Tumors express specific antigens
- 11. Monoclonal antibodies
- Tyrosine kinase inhibitors
- Bispecific monoclonal antibodies
- Side effects
- 12. Immunosuppressive effects of VEGF
- 13. Immunomodulatory effects of angiopoietin, platelet derived growth factor, and hepatocyte growth factor
- Immunomodulatory effect of angiopoietins and of platelet derived growth factor
- Immunomodulatory effect of hepatocyte growth factor
- 14. Oncolytic virus therapy
- 15. Cancer vaccines
- 16. Engineering of T cells and CAR-T therapy
- 17. Immune checkpoint inhibitors
- 18. Co-applying anti-angiogenic and immune checkpoint inhibitors
- 19. Combination therapies
- 20. Conclusions
- References
- Index
- Edition: 1
- Published: August 27, 2024
- No. of pages (Paperback): 194
- No. of pages (eBook): 180
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780443217982
- eBook ISBN: 9780443217999
DR
Domenico Ribatti
Domenico Ribatti was awarded his M.D. degree in October 1981, with full marks. In 1983, D.R. joined the Medical School as Assistant at the Institute of Human Anatomy, University of Bari. In 1984, he took the specialization in Allergology. In 1989, he spent one year in Geneva, working at the Department of Morphology (Prof. R. Montesano). In 2008, he received the honoris causa degree in Medicine and Pharmacy form the University of Timisoara (Romania). D.R. is author of 866 publications as reported in PUBmed and contributed to 50 chapters to books. Overall, his papers have been cited 51153 times.
He has published many books with both Elsevier and Springe
Affiliations and expertise
Full Professor of Human Anatomy, University of Bari Medical School, Bari, ItalyRead The Evolution of Immunotherapy Against Tumors on ScienceDirect